Researchers from WEHI and the Royal Melbourne Hospital discovered a "smoldering" molecular defect in the gut cells of inflammatory bowel disease patients. Published in Science, the study of 900 human biopsies shows that abnormal cell death signaling occurs early in the disease and persists even during clinical remission. Patients with stronger cell death signals were more likely to relapse over a two-year period. While not yielding immediate therapies, the findings offer a foundation for personalized treatments.
IBD gut cell defects
- ▪Researchers from WEHI and the Royal Melbourne Hospital identified a smoldering molecular defect in the intestinal cells of patients with inflammatory bowel disease.
- ▪The intestinal cell defect is present during the earliest stages of inflammatory bowel disease, including in patients with clinically mild cases of the disease.
- ▪The molecular defect in inflammatory bowel disease patients involves abnormal cell death and remains detectable even when patients are symptom-free and clinically stable.
Cell death drives disease
- ▪Researchers found that abnormal cell death signaling occurs very early in inflammatory bowel disease progression, representing one of the initial molecular events of the disease.
- ▪A study published in Science suggests that abnormal cell death in inflammatory bowel disease may help drive the disease itself rather than being a byproduct of inflammation.
Patient-derived organoid research
- ▪Researchers collected approximately 900 biopsies from 80 individuals with and without inflammatory bowel disease to grow mini-intestinal organoids for the study.
- ▪The WEHI-led study relied entirely on human tissue and patient-derived organoids rather than mouse models to investigate inflammatory bowel disease directly in human cells.
Molecular signals predict flares
- ▪Researchers identified the specific inflammatory signals responsible for triggering the abnormal cell death response in the intestinal cells of inflammatory bowel disease patients.
- ▪A two-year patient tracking study revealed that individuals showing stronger intestinal cell death signaling were more likely to experience an inflammatory bowel disease relapse.
Personalized treatment development
- ▪Study co-author Dr. Aysha Al-Ani stated that the findings are unlikely to produce immediate diagnostic tests or therapies but establish a foundation for future prognostic tools.
- ▪The identified molecular signals could eventually enable clinicians to develop precise monitoring tools and tailor inflammatory bowel disease treatments to an individual's molecular biology.
Story comments
Loading comments…